Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Active not recruiting 5Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 4Head & Neck 3Endocrine 3Gynecologic 2CNS 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × lenvatinib × Dermatologic × Clear all
NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled 13 charts
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡